STOK General Counsel exercised options and executed sales under 10b5-1 plan
Rhea-AI Filing Summary
Jonathan Allan, General Counsel and Corporate Secretary of Stoke Therapeutics, Inc. (STOK), reported insider transactions dated 10/03/2025. Under a Rule 10b5-1 trading plan adopted on 12/12/2024, he exercised a stock option to acquire 10,000 shares at an exercise price of $9.15 per share and immediately sold 10,000 shares at a weighted-average price of $25.065 per share. The filings show the reporting person beneficially owned 21,831 shares before the sale and 11,831 shares after the sale; he also holds an option representing 10,000 underlying shares exercisable as of 10/03/2025 that expires on 03/14/2033, leaving 34,800 total shares and equivalents reported as beneficially owned following the transactions.
Positive
- Transactions executed under a Rule 10b5-1 plan, indicating pre-established trading parameters
- Realized proceeds from sale of 10,000 shares at a weighted-average $25.065 per share after exercising at $9.15
Negative
- Direct beneficial ownership fell by 10,000 shares, from 21,831 to 11,831
- Insider sale may reduce perceived insider-held stake in the near term
Insights
TL;DR: Insider exercised options and sold shares under a pre-established 10b5-1 plan, reducing direct holdings while realizing proceeds.
The reporting person exercised a stock option to buy $0.00 in cash beyond the stated exercise price of $9.15 per share for 10,000 shares and sold those 10,000 shares at a weighted-average price of $25.065. The transactions were made pursuant to a Rule 10b5-1 plan adopted on 12/12/2024, which is commonly used to provide an affirmative defense for scheduled trades.
Key dependencies and near-term monitorables include the continuing existence of the 10b5-1 plan and any future exercises or sales of derivative holdings; the option vesting schedule noted that vesting occurred monthly beginning 04/15/2023. Investors may note the reduction in direct beneficial ownership from 21,831 to 11,831 shares reported after the sale, while total reported economic exposure including options remains 34,800.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $9.15 | $92K |
| Sale | Common Stock | 10,000 | $25.065 | $251K |
Footnotes (1)
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option vested or vests as to 1/48th of the total award on April 15, 2023, with an additional 1/48th of the total award vesting monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.
